TITLE:
A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

CONDITION:
HIV Infections

INTERVENTION:
Stavudine

SUMMARY:

      To make stavudine (d4T) available to patients with advanced HIV disease for whom no
      alternative antiretroviral is satisfactory. To study the safety and efficacy of two dose
      levels in a twice-daily regimen.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV positivity with CD4 count < 300 cells/mm3.

          -  Intolerance to or failure on approved antiretroviral therapy.

          -  Ability to provide informed consent (of parent or guardian if appropriate).

        NOTE:

          -  Incarcerated persons may be eligible to participate.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Grade 2 or worse disease-related peripheral neuropathy.

          -  Unresolved drug-related peripheral neuropathy of any severity that is attributable to
             other nucleoside analogs (AZT, ddC, ddI).

          -  Malignancy likely to require systemic chemotherapy with myelosuppressive or
             neurotoxic drugs in the first 3 months of stavudine treatment.

          -  Pregnancy (physicians of pregnant patients may contact Bristol-Myers to determine
             eligibility for stavudine therapy in another protocol).

        Strongly discouraged:

          -  AZT, ddI, ddC, and other antiretroviral agents.
      
